<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117568">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01752569</url>
  </required_header>
  <id_info>
    <org_study_id>STH16059</org_study_id>
    <secondary_id>2011-003099-35</secondary_id>
    <nct_id>NCT01752569</nct_id>
  </id_info>
  <brief_title>A Study of Selumetinib in Patients With Kaposi's Sarcoma</brief_title>
  <acronym>SCART</acronym>
  <official_title>Phase I/II Study of Oral MEK Inhibitor Selumetinib (AZD6244 Hyd-Sulphate) in Combination With Highly Active Anti-Retroviral Therapy (HAART) in AIDS-associated Kaposi's Sarcoma (KS).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheffield Teaching Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK Clinical Trials Unit, Birmingham UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fisher Clinical Services Ltd. (drug supply)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK (funding)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sheffield</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheffield Teaching Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer is a leading cause of death in individuals living with HIV, and Kaposi's sarcoma (KS)
      remains the commonest HIV-associated cancer. KS results from co-infection with HIV and
      another virus, HHV-8. Laboratory studies have shown that HHV-8 viral proteins stimulate
      intracellular signalling pathways within KS lesions which promotes their growth. Selumetinib
      targets these signalling pathways and may therefore be a useful new therapy for KS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Objective Response Rates</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity of Selumetinib in combination with HAART.</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary outcome measure is to identify the safe recommended phase II dose using CTCAE version 4.0 criteria to assess dose limiting toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PBMC sub-study</measure>
    <time_frame>2.5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis of PBMC in a sub-study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of completed cycles</measure>
    <time_frame>2.5.years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of cycles of Selumetinib treatment in combination with HAART.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV viral load and CD4 count</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAART Drug levels</measure>
    <time_frame>1 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Phase I only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Selumetinib and metabolite serum levels</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Phase I only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum angiogenic biomarkers levels</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacodynamic measures of Selumetinib in combination with HAART - serum angiogenic biomarker levels and pERK in tumour tissue.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>AIDS-related Kaposi's Sarcoma</condition>
  <arm_group>
    <arm_group_label>Selumetinib treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-finding study of selumetinib in combination with HAART (phase I) and efficacy at recommended phase 2 dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selumetinib</intervention_name>
    <description>Dose schedule:
-1 75 mg od (75 total) --
(starting) 50 mg bd (100 total)
75 mg bd (150 total)
100 mg bd (200 total) Selumetinib should be taken twice daily approximately 12 hours apart with water (for BD doses), at least 2 hours after a meal and 1 hour before the next meal. Selumetinib capsules will be administered in a continuous 21 day cycle (6 cycles), unless disease progression occurs.</description>
    <arm_group_label>Selumetinib treatment</arm_group_label>
    <other_name>AZD6244</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed KS.

          -  Measurable disease according to ACTG criteria.

          -  Evidence of disease progression in the past 6 months, without anticancer treatment
             since progression.

          -  Progressive cutaneous or nodal KS not requiring chemotherapy OR progressive KS
             following cytotoxic chemotherapy.

          -  Adequate haematological function:

               -  Haemoglobin ≥ 9 g/dL

               -  Absolute neutrophil count ≥ 1.5 x 10 9/L

               -  Platelets ≥ 100 x 10 9/L

          -  Adequate hepatic function:

               -  Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)

               -  ALT ≤ 2.5 x ULN

               -  AST ≤ 2.5 x ULN

          -  Adequate renal function:

               -  Serum creatinine clearance &gt; 50 ml/min (Cockcroft-Gault formula or 24 hour urine
                  collection).

          -  Left ventricular function &gt;50% normal

          -  Age ≥ 18 years.

          -  ECOG performance status ≤ 2.

          -  For selumetinib, women of child bearing age and child bearing potential MUST have a
             negative pregnancy test prior to study entry AND be using an adequate contraception
             method, which must be continued while on treatment and for at least 4 weeks after the
             study treatment has ended.

          -  Male patients must agree to use an effective contraception method while on treatment
             and for at least 16 weeks after the study treatment has ended (barrier contraception
             is recommended for all individuals living with HIV).

          -  Written informed consent

        Exclusion Criteria:

          -  HIV viral load &gt; 200 copies/ml.

          -  Any previous treatment with a Ras, Raf or MEK inhibitor.

          -  Active opportunistic infections.

          -  Known hepatitis B, hepatitis C.

          -  Clinical evidence of uncontrolled hypertension (systolic BP &gt; 150 mmHg or diastolic
             BP &gt; 90 mmHg on 2 readings ≥ 1 hour apart).

          -  Clinical evidence of heart failure (≥NYHA Class II).

          -  Clinical evidence of atrial fibrillation (heart rate &gt; 100 bpm) or unstable ischaemic
             heart disease (MI within 6 months prior to starting treatment or angina requiring the
             use of nitrates &gt; once weekly).

          -  Major surgery within 4 weeks prior to starting selumetinib.

          -  Evidence of any psychological, familial, sociological or geographical condition
             potentially hampering protocol compliance.

          -  Clinical judgement by the Investigator that the patient should not participate in the
             study.

          -  Refractory nausea, vomiting, chronic gastrointestinal diseases (e.g. inflammatory
             bowel disease) or significant bowel resection that would preclude adequate
             absorption.

          -  Treatment with any investigational product within 28 days of registration

          -  Pregnant or breast-feeding women.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Bower, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chelsea &amp; Westminster Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diana Ritchie, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beatson Institute, Glasgow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarah Westwell, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brighton and Sussex University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Leahy, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christie Hospital, Manchester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Swethajit Biswas, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Victoria Infirmary, Newcastle</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kate Fife, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Addenbrookes Hospital, Cambridge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Nicolson, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leceister Royal Infirmary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Siow-Ming Lee, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Simmonds, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southampton University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Penella Woll</last_name>
    <phone>01142265235</phone>
    <email>p.j.woll@sheffield.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Crack</last_name>
    <phone>01214147627</phone>
    <email>l.r.crack@bham.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brighton and Sussex University Hospitals</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Sellick</last_name>
      <phone>01273 696955</phone>
      <phone_ext>3523</phone_ext>
      <email>Victoria.Sellick@bsuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Sarah Westwell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Gladwell</last_name>
    </contact>
    <investigator>
      <last_name>Kate Fife</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson Institute</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Diana Ritchie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy King</last_name>
      <phone>0116 258 6318</phone>
      <email>amy.king@uhl-tr.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Stephen Nicolson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chelsea &amp; Westminster Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Shields</last_name>
      <phone>020 3315 6101</phone>
      <email>Alice.Shields@chelwest.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Paracchini</last_name>
      <phone>020 3315 2090</phone>
      <phone_ext>5036</phone_ext>
      <email>barbara.paracchini@chelwest.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Bower</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Siow-Ming Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Smina Shahban</last_name>
      <phone>0161 918 7355</phone>
      <email>smina.shahban@christie.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Michael Leahy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Informary</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Swethajit Biswas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Crabtree</last_name>
      <phone>01142 265 229</phone>
      <email>c.crabtree@sheffield.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Penella Woll</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Peter Simmonds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.hpa.org.uk</url>
    <description>Health Protection Agency &quot;HIV in the United Kingdom&quot; Report 2009</description>
  </link>
  <reference>
    <citation>Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008 May 1;26(13):2139-46. Epub 2008 Apr 7.</citation>
    <PMID>18390968</PMID>
  </reference>
  <reference>
    <citation>Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH, Cantarini MV, Morris C, George SM, Smith PD, van Herpen CM. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res. 2010 Mar 1;16(5):1613-23. doi: 10.1158/1078-0432.CCR-09-2483. Epub 2010 Feb 23.</citation>
    <PMID>20179232</PMID>
  </reference>
  <reference>
    <citation>Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, Pover G, Tebbutt NC. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs. 2012 Jun;30(3):1216-23. doi: 10.1007/s10637-011-9687-4. Epub 2011 May 19. Erratum in: Invest New Drugs. 2012 Jun;30(3):1272-3.</citation>
    <PMID>21594619</PMID>
  </reference>
  <reference>
    <citation>Bower M, Collins S, Cottrill C, Cwynarski K, Montoto S, Nelson M, Nwokolo N, Powles T, Stebbing J, Wales N, Webb A; AIDS Malignancy Subcommittee. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med. 2008 Jul;9(6):336-88. doi: 10.1111/j.1468-1293.2008.00608.x.</citation>
    <PMID>18705759</PMID>
  </reference>
  <reference>
    <citation>Cooley T, Henry D, Tonda M, Sun S, O'Connell M, Rackoff W. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Oncologist. 2007 Jan;12(1):114-23.</citation>
    <PMID>17227906</PMID>
  </reference>
  <reference>
    <citation>Di Lorenzo G, Konstantinopoulos PA, Pantanowitz L, Di Trolio R, De Placido S, Dezube BJ. Management of AIDS-related Kaposi's sarcoma. Lancet Oncol. 2007 Feb;8(2):167-76. Review.</citation>
    <PMID>17267331</PMID>
  </reference>
  <reference>
    <citation>Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1989 Sep;7(9):1201-7.</citation>
    <PMID>2671281</PMID>
  </reference>
  <reference>
    <citation>Sharma-Walia N, Krishnan HH, Naranatt PP, Zeng L, Smith MS, Chandran B. ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection. J Virol. 2005 Aug;79(16):10308-29.</citation>
    <PMID>16051824</PMID>
  </reference>
  <reference>
    <citation>Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, Bower M. A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy. Lancet. 2006 May 6;367(9521):1495-502. Review.</citation>
    <PMID>16679162</PMID>
  </reference>
  <reference>
    <citation>Tulpule A, Groopman J, Saville MW, Harrington W Jr, Friedman-Kien A, Espina BM, Garces C, Mantelle L, Mettinger K, Scadden DT, Gill PS. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer. 2002 Jul 1;95(1):147-54.</citation>
    <PMID>12115328</PMID>
  </reference>
  <reference>
    <citation>Vart RJ, Nikitenko LL, Lagos D, Trotter MW, Cannon M, Bourboulia D, Gratrix F, Takeuchi Y, Boshoff C. Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. Cancer Res. 2007 May 1;67(9):4042-51.</citation>
    <PMID>17483315</PMID>
  </reference>
  <reference>
    <citation>Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Mäkinen T, Elliman S, Flanagan AM, Alitalo K, Boshoff C. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet. 2004 Jul;36(7):687-93. Epub 2004 Jun 27.</citation>
    <PMID>15220918</PMID>
  </reference>
  <reference>
    <citation>Xie J, Ajibade AO, Ye F, Kuhne K, Gao SJ. Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways. Virology. 2008 Feb 5;371(1):139-54. Epub 2007 Oct 26.</citation>
    <PMID>17964626</PMID>
  </reference>
  <reference>
    <citation>Yang X, Gabuzda D. Regulation of human immunodeficiency virus type 1 infectivity by the ERK mitogen-activated protein kinase signaling pathway. J Virol. 1999 Apr;73(4):3460-6.</citation>
    <PMID>10074203</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 14, 2012</lastchanged_date>
  <firstreceived_date>August 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Kaposi's sarcoma</keyword>
  <keyword>Anti-retroviral therapy</keyword>
  <keyword>AIDS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>AIDS-Related Opportunistic Infections</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
